The World Phosphodiesterase (PDE) Inhibitors Market to 2023 - Rising Prevalence of Erectile Dysfunction Elevates Growth Rates

| Source: Research and Markets Research and Markets

Dublin, July 29, 2019 (GLOBE NEWSWIRE) -- The "Global Phosphodiesterase (PDE) inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Rising prevalence of erectile dysfunction (ED)

The etiology of ED can be attributed to multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia. In addition, the consumption of certain medicines and substance abuse can lead to ED. As most of these factors are related to lifestyle changes, the prevalence of ED is increasing globally.

Rapid urbanization, and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to ED. Thus, the increase in the incidence of ED is expected to boost the adoption of PDE inhibitors and drive the market at a CAGR of almost 6% during the forecast period.

Rising burden of chronic diseases

Chronic diseases are among the leading causes of death and contribute to a significant portion of annual healthcare expenditure. Rising healthcare costs associated with chronic diseases such as heart disease, stroke, diabetes and prediabetes is expected to lead to an increase in the adoption of PDE5 inhibitors. Thus, an increase in the economic and health burden of these diseases will ensure continuous or increased use of PDE5 inhibitors for their remission, which will promote market growth during the forecast period.

Market Dynamics

The report also looks at factors such as growing adoption of poor lifestyle habits, rising prevalence of erectile dysfunction (ED), and availability of next-generation PDE inhibitors. However, potent drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and launch of generics may hamper the growth of the phosphodiesterase inhibitors industry over the forecast period.

Segments Covered

The phosphodiesterase inhibitors market analysis considers sales from oral, topical, and other RoA. This analysis also considers the sales of phosphodiesterase inhibitors in Asia, Europe, North America, and RoW.

In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low cost, and accurate dosage and stability will play a significant role in the oral segment to maintain its market position.

Competitive Landscape

With the presence of several major players, the global phosphodiesterase inhibitors market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphodiesterase inhibitors manufacturers, that include:

  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Vivus Inc.

Also, the phosphodiesterase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY APPLICATION

  • Comparison by application
  • Oral - Market size and forecast 2018-2023
  • Topical - Market size and forecast 2018-2023
  • Other RoA - Market size and forecast 2018-2023
  • Market opportunity by application

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

  • Application of novel technologies for PDE inhibitors development
  • Growing geriatric population
  • Rising burden of chronic diseases

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly & Co.
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Vivus Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ohy00k

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


            











    

        

        
Contact Data